{"created":"2023-06-19T12:16:32.044089+00:00","id":1226,"links":{},"metadata":{"_buckets":{"deposit":"95defa5d-ec59-4706-bfe3-8a7904da9ef8"},"_deposit":{"created_by":3,"id":"1226","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"1226"},"status":"published"},"_oai":{"id":"oai:hachinohe-hachitan.repo.nii.ac.jp:00001226","sets":["248:374"]},"author_link":["1741"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-03-29","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"58","bibliographicPageEnd":"138","bibliographicPageStart":"131","bibliographic_titles":[{"bibliographic_title":"八戸学院大学紀要"}]}]},"item_10002_description_6":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"がん治療における免疫療法は、抗がん薬による治療、手術療法および放射線療法に次ぐ第4の治療法である。近年のがんの病因、とくに生物学的特性に関する分子学的研究の進展により、遺伝子レベルでのがん免疫についての知見が得られ、新しい免疫チェックポイント阻害薬が臨床で用いられているが、その対象疾患はまだ少ない。本稿ではがん免疫療法の理論的背景、研究進展の経緯とともに、抗PD-1　(Programmed death-1)、抗PD-L1（Programmed death-ligannd1)など、オブジーボ®に代表される免疫チェックポイン阻害薬による対象疾患や、生じる可能性がある有害事象とともに、現在フェーズⅠ、Ⅱが進行中の新規の免疫チェックポイント治療薬について述べる。","subitem_description_type":"Other"}]},"item_10002_select_24":{"attribute_name":"論文種別","attribute_value_mlt":[{"subitem_select_item":"総説"}]},"item_10002_select_25":{"attribute_name":"学部学科","attribute_value_mlt":[{"subitem_select_item":"健康医療学部看護学科"}]},"item_10002_select_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_select_item":"八戸学院大学"}]},"item_10002_select_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_select_item":"2187-8102"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"高橋, 正知"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-03-29"}],"displaytype":"simple","filename":"八戸学院大学紀要第58号0011.pdf","filesize":[{"value":"733.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"PDF(本文)","url":"https://hachinohe-hachitan.repo.nii.ac.jp/record/1226/files/八戸学院大学紀要第58号0011.pdf"},"version_id":"4e7101e7-3f63-410e-94be-370769866fee"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"がん治療","subitem_subject_scheme":"Other"},{"subitem_subject":"がん免疫療法","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫チェックポイント阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"cancer therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"cancer immunotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immune checkpoint inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"がん治療における免疫チェックポイント阻害薬","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"がん治療における免疫チェックポイント阻害薬"},{"subitem_title":"Immune checkpoint inhibitor in cancer therapy","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"3","path":["374"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-03-29"},"publish_date":"2019-03-29","publish_status":"0","recid":"1226","relation_version_is_last":true,"title":["がん治療における免疫チェックポイント阻害薬"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-06-19T12:23:16.832477+00:00"}